TERN - NASDAQ
Terns Pharmaceuticals, Inc.
$52.95
+0.0000%Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
At a Glance
Live SnapshotTerns Pharmaceuticals, Inc. Management Team
Ms. Melita Sun Jung
Chief Business Officer
Compensation
$508,886
Mr. Scott Harris
Chief Development Officer
Ms. Amy L. Burroughs M.B.A.
Chief Executive Officer & Director
Compensation
$1,007,081
Mr. Andrew W. Gengos
Chief Financial Officer
Mr. Andrew W. Gengos
Chief Financial Officer & Head of Corporate Development
Ms. Caryn Gordon McDowell J.D.
Chief Legal Officer
Dr. Emil T. Kuriakose M.D.
Chief Medical Officer
Ms. Robin Andrulevich
Chief People Officer
Mr. James Kanter
Senior Vice President of CMC
Ms. Debra Sieminski
Senior Vice President of Medical Affairs
Ms. Yasameen Qazen
Senior Vice President of Regulatory Affairs & Quality Assurance
Dr. Jeffrey R. Jasper Ph.D.
Senior Vice President of Research
Terns Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $148K and sold $6.13M worth of TERN shares, resulting in $5.99M of net selling activity.
3 Months
0
0.00
12.8K
599.77K
-600K
-$600K
3-6 Months
0
0.00
135.1K
5.08M
-5.1M
-$5.08M
6-9 Months
0
0.00
25.5K
448.77K
-449K
-$449K
9-12 Months
38.3K
148.34K
853
3.64K
+145K
+$145K
Top Buyers
Burroughs Amy L.
Director, Officer: Chief Executive Officer
$90K
Gengos Andrew
Officer: Chief Financial Officer
$58K
Top Sellers
Burroughs Amy L.
Director, Officer: Chief Executive Officer
$5.62M
Quigley Jill M.
Director
$441K
Kuriakose Emil
Officer: Chief Medical Officer
$69K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $5.99M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
TERN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 10, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 12, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 16, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.